Yale School of Medicine

Yale researchers have discovered that nasal vaccine boosters can trigger robust immune responses in the respiratory tract without requiring adjuvants, offering a potential breakthrough for respiratory disease prevention.

A phase 3b clinical trial demonstrated that Rebyota (fecal microbiota, live-jslm) administered via colonoscopy achieved a 95.1% treatment success rate in preventing recurrent C. difficile infection.

Despite historical limitations of immunotherapy in treating glioblastoma, CAR T-cell therapy is showing promising early results, particularly in patients with EGFRvIII mutations, offering new hope in this challenging field.

Recent clinical trials evaluating immunotherapy agents in myelodysplastic syndromes (MDS) have shown mixed results, with sabatolimab plus hypomethylating agents demonstrating numerical but not statistically significant survival benefits.

The FDA announced voluntary recalls of six popular acne products containing benzoyl peroxide after testing revealed elevated benzene levels above the conditional limit of two parts per million.

Exploratory analysis of the phase 3 ADAURA trial reveals plasma-based, tumor-informed minimal residual disease (MRD) detection can predict disease recurrence in resected EGFR-mutated NSCLC, with MRD positivity preceding clinical recurrence by approximately 4.7 months.

Analysis from I-SPY2 trial demonstrates that hormone receptor-positive, HER2-negative breast cancers with MammaPrint High-2 classification show molecular and clinical similarities to triple-negative breast cancers.

Yale dermatology expert Dr. Christopher Bunick presents compelling data showing JAK inhibitors like upadacitinib and abrocitinib provide faster skin and itch relief compared to dupilumab in atopic dermatitis treatment.

A comprehensive 12-year PURE study across 17 countries shows significant underutilization of secondary prevention medications for cardiovascular disease, with usage rates dropping to 31.3% in the final study visit.

Yale researchers have developed JomCare, an innovative mobile app designed to reduce HIV transmission risk by targeting sexualized drug use behaviors among gay and bisexual men.